Back to Browse Journals » Breast Cancer: Targets and Therapy » Volume 3

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women

Authors Vogel VG

Published 20 October 2011 Volume 2011:3 Pages 127—137


Review by Single-blind

Peer reviewer comments 5

Victor G Vogel
Cancer Institute, Geisinger Health System, Danville, PA, USA

Abstract: Risk factors allow us to define women who are at increased lifetime risk for breast cancer, and the most important factor is age. Benign breast disease increases risk, and the most important histologies are atypical lobular or ductal hyperplasia and lobular carcinoma in situ. Family history of breast cancer among first-degree relatives (mother, sisters, daughters) also increases risk. Quantitative measures of risk give accurate predictions of breast cancer incidence for groups of women but not for individual subjects. Multiple published, randomized controlled trials, which employed selective estrogen receptor (ER) modulators (SERMs), have demonstrated consistent reductions of 35% or greater in the risk of ER-positive invasive and noninvasive breast cancer in postmenopausal women. Professional organizations in the US now recommend the use of SERMs to reduce the risk of breast cancer in high-risk, postmenopausal women. Raloxifene and tamoxifen reduce the risk of ER-positive invasive breast cancer with equal efficacy, but raloxifene is associated with a lower risk of thromboembolic disease, benign uterine conditions, and cataracts than tamoxifen in postmenopausal women. No evidence exists establishing whether a reduction in breast cancer risk from either agent translates into reduced breast cancer mortality. Overall quality of life is similar with raloxifene or tamoxifen, but the incidence of dyspareunia, weight gain, and musculoskeletal complaints is higher with raloxifene use, whereas vasomotor symptoms, bladder incontinence, gynecologic symptoms, and leg cramps were higher with tamoxifen use.

Keywords: selective estrogen receptor modulators (SERMs), raloxifene, risk reduction, chemoprevention

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Readers of this article also read:

Degos disease – malignant atrophic papulosis or cutaneointestinal lethal syndrome: rarity of the disease

Pirolla E, Fregni F, Miura IK, Misiara AC, Almeida F, Zanoni E

Clinical and Experimental Gastroenterology 2015, 8:141-147

Published Date: 16 April 2015

Developments in flexible endoscopic surgery: a review

Feussner H, Becker V, Bauer M, Kranzfelder M, Schirren R, Lüth T, Meining A, Wilhelm D

Clinical and Experimental Gastroenterology 2015, 8:31-42

Published Date: 18 December 2014

Population-based service mammography screening: the Icelandic experience

Sigurdsson K, Ólafsdóttir EJ

Breast Cancer: Targets and Therapy 2013, 5:17-25

Published Date: 9 May 2013

FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation

Szlachcic A, Pala K, Zakrzewska M, Jakimowicz P, Wiedlocha A, Otlewski J

International Journal of Nanomedicine 2012, 7:5915-5927

Published Date: 29 November 2012

New developments in the treatment of HER2-positive breast cancer

Nahta R

Breast Cancer: Targets and Therapy 2012, 4:53-64

Published Date: 7 May 2012

Breast reconstruction: current and future options

Paul Jr H, Prendergast TI, Nicholson B, White S, Frederick WA

Breast Cancer: Targets and Therapy 2011, 3:93-99

Published Date: 17 August 2011

The p53 breast cancer tissue biomarker in Indian women

Patil V, Tayade M, Pingale S, Dalvi S, Rajekar R, Deshmukh H, Patil S, Singhai R

Breast Cancer: Targets and Therapy 2011, 3:71-78

Published Date: 11 August 2011

Preparation of a ligustrazine ethosome patch and its evaluation in vitro and in vivo

Xingyan Liu1 Hong Liu, Jianqiang Liu, Zhiwei He, et al

International Journal of Nanomedicine 2011, 6:241-247

Published Date: 27 January 2011

Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting

Matthew M Seavey, Yvonne Paterson

Breast Cancer: Targets and Therapy 2009, 1:19-30

Published Date: 5 October 2009